MCID: ESP021
MIFTS: 77

Esophageal Cancer

Categories: Genetic diseases, Rare diseases, Cancer diseases, Gastrointestinal diseases, Skin diseases

Aliases & Classifications for Esophageal Cancer

MalaCards integrated aliases for Esophageal Cancer:

Name: Esophageal Cancer 57 38 12 53 75 37 13 43 15
Esophageal Squamous Cell Carcinoma 57 59 75 6
Esophageal Carcinoma 12 55 15 73
Carcinoma of Esophagus 12 29 6
Esophageal Squamous Cell Carcinoma, Somatic 57 6
Esophageal Carcinoma, Somatic 57 6
Gastric Cardia Adenocarcinoma 75 73
Esophageal Neoplasms 44 73
Esophageal Neoplasm 76 29
Esophagus Cancer 12 53
Escc 59 75
Malignant Tumor of the Middle Third of the Esophagus 12
Malignant Neoplasm of Proximal Third of Esophagus 12
Malignant Neoplasm of Middle Third of Oesophagus 12
Malignant Neoplasm of Distal Third of Esophagus 12
Malignant Neoplasm of Lower Third of Oesophagus 12
Malignant Neoplasm of Middle Third of Esophagus 73
Malignant Tumor of Proximal Third of Esophagus 12
Malignant Tumor of Distal Third of Esophagus 12
Malignant Neoplasm of Upper Third Esophagus 12
Squamous Cell Carcinoma of the Esophagus 59
Malignant Tumor of Abdominal Esophagus 12
Squamous Cell Carcinoma of Esophagus 73
Esophageal Epidermoid Carcinoma 59
Squamous Cell Esophageal Cancer 55
Malignant Neoplasm of Esophagus 73
Esophageal Cancer, Somatic 57
Ca Middle Third Oesophagus 12
Aerodigestive Tract Cancer 75
Ca Lower Third Oesophagus 12
Carcinoma of Oesophagus 12
Cancer of Oesophagus 12
Cancer of Esophagus 12
Cancer, Esophageal 40
Escr 75

Characteristics:

Orphanet epidemiological data:

59
squamous cell carcinoma of the esophagus
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/100000 (Worldwide); Age of onset: Adult; Age of death: adult;

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
esophageal cancer:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Esophageal Cancer

OMIM : 57 Esophageal cancer, particularly esophageal squamous cell carcinoma (ESCC), is one of the most common cancers worldwide. Both environmental and genetic risk factors play a role in the pathogenesis of the disorder. In Europe and North America, heavy smoking, alcohol consumption, and increased body mass index (BMI) are the main environmental risk factors. In contrast, the particularly high incidence of ESCC in some areas of China, central Asia, and southern Africa is associated with nutritional deficiencies, high intake of nitrosamine-rich or pickled vegetables, and low socioeconomic status; smoking, alcohol consumption, and BMI play a lesser role in these populations. There is a tendency for familial aggregation of ESCC in high-risk geographic areas, suggesting a genetic component to increased susceptibility. Gastric cardia adenocarcinoma is another common type of cancer in China that shows similarities to ESCC in terms of geographic distribution and environmental risk factors (summary by Wang et al., 2010 and Abnet et al., 2010). (133239)

MalaCards based summary : Esophageal Cancer, also known as esophageal squamous cell carcinoma, is related to mucoepidermoid esophageal carcinoma and adenocarcinoma, and has symptoms including abdominal pain, constipation and coughing. An important gene associated with Esophageal Cancer is TGFBR2 (Transforming Growth Factor Beta Receptor 2), and among its related pathways/superpathways are MicroRNAs in cancer and Gastric cancer. The drugs Photodynamic Therapy (& Photofrin) and Photofrin have been mentioned in the context of this disorder. Affiliated tissues include the esophagus, lung and lymph node, and related phenotypes are abnormality of the voice and clinodactyly of the 5th toe

UniProtKB/Swiss-Prot : 75 Esophageal cancer: A malignancy of the esophagus. The most common types are esophageal squamous cell carcinoma and adenocarcinoma. Cancer of the esophagus remains a devastating disease because it is usually not detected until it has progressed to an advanced incurable stage.

NIH Rare Diseases : 53 Esophageal cancer is a cancer of the esophagus, the hollow tube that carries food and liquids from the throat to the stomach. As the cancer grows, symptoms may include painful or difficult swallowing, weight loss and coughing up blood. The exact cause is usually not known, but both environmental and genetic factors are throught to play a role in the development of this condition. In the United States, risk factors for developing esophageal cancer include smoking, heavy drinking, obesity, and damage from acid reflux. Treatments include surgery, radiation, chemotherapy, and laser therapy. Some patients may also need nutritional support, since the cancer or treatment may make it hard to swallow.

MedlinePlus : 43 The esophagus is a hollow tube that carries food and liquids from your throat to your stomach. Early esophageal cancer usually does not cause symptoms. Later, you may have symptoms such as Painful or difficult swallowing Weight loss A hoarse voice or cough that doesn't go away You're at greater risk for getting esophageal cancer if you smoke, drink heavily, or have acid reflux. Your risk also goes up as you age Your doctor uses imaging tests and a biopsy to diagnose esophageal cancer. Treatments include surgery, radiation, and chemotherapy. You might also need nutritional support, since the cancer or treatment may make it hard to swallow. NIH: National Cancer Institute

Disease Ontology : 12 A gastrointestinal system cancer that is located in the esophagus.

Wikipedia : 76 Esophageal cancer is cancer arising from the esophagus—the food pipe that runs between the throat and... more...

Related Diseases for Esophageal Cancer

Diseases related to Esophageal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 205)
# Related Disease Score Top Affiliating Genes
1 mucoepidermoid esophageal carcinoma 35.1 TP53 WWOX
2 adenocarcinoma 34.0 EGFR HRAS PIK3CA SMAD4 TGFBR2 TP53
3 esophageal basaloid squamous cell carcinoma 33.8 EGFR TP53 WWOX
4 squamous cell carcinoma 32.5 CASC9 EGFR HRAS LZTS1 PIK3CA RNF6
5 gastric cancer 32.1 CASC9 EGFR MIR106A MIR21 MIR34A PIK3CA
6 esophagus adenocarcinoma 31.7 MIR21 PIK3CA SMAD4 TP53
7 lung cancer 31.7 CASC9 EGFR HRAS MIR106A MIR126 MIR148A
8 small cell cancer of the lung 31.6 EGFR MIR21 PIK3CA TP53
9 nasopharyngeal carcinoma 31.5 CASC9 EGFR HRAS PIK3CA TGFBR2 TP53
10 hepatocellular carcinoma 31.5 EGFR HRAS MIR126 MIR148A MIR21 MIR30E
11 oral squamous cell carcinoma 31.5 MIR126 MIR148A MIR21 MIR34A
12 breast cancer 31.4 EGFR HRAS MIR126 MIR148A MIR21 MIR30E
13 dermatomyositis 31.4 MIR148A MIR21 MIR34A
14 pancreas adenocarcinoma 31.4 EGFR HRAS PIK3CA SMAD4 TP53
15 colorectal cancer 31.4 DCC EGFR HRAS MIR106A MIR126 MIR21
16 leukemia, chronic lymphocytic 31.3 HRAS MIR16-2 MIR21 MIR34A TP53
17 colorectal adenocarcinoma 31.3 EGFR HRAS TP53
18 cervical cancer 31.2 HRAS MIR21 PIK3CA SMAD4 TP53
19 squamous cell carcinoma, head and neck 31.2 EGFR HRAS MIR148A MIR21 MIR373 PIK3CA
20 prostate cancer 31.1 EGFR HRAS MIR106A MIR126 MIR148A MIR21
21 tylosis with esophageal cancer 12.5
22 gastric cardia adenocarcinoma 12.5
23 carcinoma of esophagus, salivary gland type 12.0
24 undifferentiated carcinoma of esophagus 12.0
25 esophageal cancer, childhood 12.0
26 breast squamous cell carcinoma 11.6 EGFR PIK3CA TP53
27 glioma 11.6 EGFR MIR21 MIR34A PIK3CA TP53
28 brain stem glioma 11.5 EGFR PIK3CA TP53
29 glioblastoma 11.5 EGFR HRAS MIR21 MIR34A PIK3CA TP53
30 cell type cancer 11.5 EGFR HRAS TP53 WWOX
31 estrogen-receptor positive breast cancer 11.5 EGFR PIK3CA TP53
32 brain ependymoma 11.5 EGFR TP53
33 malignant ovarian surface epithelial-stromal neoplasm 11.5 EGFR HRAS PIK3CA TP53
34 ovary epithelial cancer 11.5 EGFR HRAS PIK3CA TP53
35 female reproductive organ cancer 11.5 EGFR HRAS PIK3CA TP53
36 respiratory system cancer 11.5 EGFR HRAS PIK3CA TP53
37 alcohol dependence 11.5
38 glioblastoma multiforme 11.5 EGFR MIR21 PIK3CA TP53
39 oral cancer 11.5 EGFR MIR21 TP53
40 uterine carcinosarcoma 11.5 EGFR HRAS PIK3CA TP53
41 esophagus squamous cell carcinoma 11.4
42 bile duct carcinoma 11.4 EGFR PIK3CA TP53
43 rare adenocarcinoma of the breast 11.4 PIK3CA TP53
44 ethmoid sinus cancer 11.4 EGFR HRAS PIK3CA
45 gastrointestinal system cancer 11.4 EGFR HRAS PIK3CA SMAD4 TP53 WWOX
46 ethmoid sinus adenocarcinoma 11.4 EGFR HRAS PIK3CA
47 lung adenoid cystic carcinoma 11.4 EGFR HRAS PIK3CA
48 oral cavity cancer 11.4 EGFR PIK3CA TP53
49 acneiform dermatitis 11.4 EGFR HRAS PIK3CA
50 prostate squamous cell carcinoma 11.4 HRAS PIK3CA TP53

Comorbidity relations with Esophageal Cancer via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Deficiency Anemia
Esophageal Disease Esophagitis
Familial Atrial Fibrillation Heart Disease
Neutropenia Protein-Energy Malnutrition
Swallowing Disorders

Graphical network of the top 20 diseases related to Esophageal Cancer:



Diseases related to Esophageal Cancer

Symptoms & Phenotypes for Esophageal Cancer

Symptoms via clinical synopsis from OMIM:

57
Oncology:
esophageal cancer

Misc:
frequent loss of heterozygosity of apc and/or mcc genes


Clinical features from OMIM:

133239

Human phenotypes related to Esophageal Cancer:

59 32 (show all 17)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of the voice 59 32 frequent (33%) Frequent (79-30%) HP:0001608
2 clinodactyly of the 5th toe 59 32 hallmark (90%) Very frequent (99-80%) HP:0001864
3 nausea and vomiting 59 32 frequent (33%) Frequent (79-30%) HP:0002017
4 lymphadenopathy 59 32 frequent (33%) Occasional (29-5%) HP:0002716
5 feeding difficulties in infancy 59 32 hallmark (90%) Very frequent (99-80%) HP:0008872
6 esophageal carcinoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0011459
7 cough 59 32 frequent (33%) Frequent (79-30%) HP:0012735
8 chest pain 59 32 frequent (33%) Frequent (79-30%) HP:0100749
9 squamous cell carcinoma 32 HP:0002860
10 abnormality of the neck 32 frequent (33%) HP:0000464
11 obesity 32 occasional (7.5%) HP:0001513
12 weight loss 32 hallmark (90%) HP:0001824
13 dysphagia 32 hallmark (90%) HP:0002015
14 gastroesophageal reflux 32 frequent (33%) HP:0002020
15 abnormal intestine morphology 32 occasional (7.5%) HP:0002242
16 recurrent singultus 32 frequent (33%) HP:0100247
17 barrett esophagus 32 occasional (7.5%) HP:0100580

UMLS symptoms related to Esophageal Cancer:


abdominal pain, constipation, coughing, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, snoring, tinnitus, sore throat, vertigo/dizziness, equilibration disorder, gastrointestinal gas

MGI Mouse Phenotypes related to Esophageal Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.28 DCC EGFR HRAS LZTS1 PIK3CA SMAD4

Drugs & Therapeutics for Esophageal Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Photodynamic Therapy (& Photofrin) 18 PORFIMER SODIUM Sanofi-aventis January, 1996
2
Photofrin 18 PORFIMER SODIUM QLT January 1998

Drugs for Esophageal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 495)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menthol Approved Phase 4,Phase 3,Phase 2,Not Applicable 2216-51-5 16666
2
Pravastatin Approved Phase 4 81093-37-0 54687
3
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 51-43-4 5816
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
5
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
6
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
7
Racepinephrine Approved Phase 4,Phase 2,Not Applicable 329-65-7 838
8
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 61825-94-3 5310940 9887054 43805 6857599
9
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 15663-27-1 84093 441203 2767
10
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
11
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
12
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 97682-44-5, 100286-90-6 60838
13
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68538-85-2
14
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
15
Dobutamine Approved Phase 4 34368-04-2 36811
16
Norepinephrine Approved Phase 4 51-41-2 439260
17
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
18
Phenylephrine Approved Phase 4 59-42-7 6041
19
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
20
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
21
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
22
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
23
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
24
Iron Approved Phase 4,Phase 1 7439-89-6 23925
25
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
26
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
27
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
28
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
29
Camptothecin Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7689-03-4
30 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Anticholesteremic Agents Phase 4
32 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
33 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
34 Hypolipidemic Agents Phase 4,Phase 1
35 Lipid Regulating Agents Phase 4,Phase 1
36 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
37 Epinephryl borate Phase 4,Phase 2,Not Applicable
38 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
39 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
43 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Early Phase 1
44 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
46 Proton Pump Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
47 Hematinics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
48 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Antidotes Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 1296)
# Name Status NCT ID Phase Drugs
1 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
2 Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
3 A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma Unknown status NCT00642239 Phase 4 placebo;Sodium Glycididazole
4 Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery Unknown status NCT00790140 Phase 4
5 Postoperative Pain Management After Minimally Invasive Esophagectomy Unknown status NCT02042313 Phase 4
6 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
7 Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer Completed NCT00911092 Phase 4 Chemotherapy (Fluorouracil and Cisplatin)
8 INEC Study: Immuno-modulating Enteral Nutrition in Cancer Completed NCT00333099 Phase 4
9 Decreasing Postoperative Complications by Goal-Directed Fluid Therapy During Esophageal Resection Completed NCT01416077 Phase 4
10 The Effect of Nutritional Counseling for Cancer Patients Completed NCT01962272 Phase 4
11 Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus. Completed NCT00754468 Phase 4
12 Deep Neuromuscular Relaxation in Patients for Thoraco-laparoscopic Esophagectomy Completed NCT02320734 Phase 4 Rocuronium
13 The Effects of Dexmedetomidine on Inflammatory Mediators After One Lung Ventilation During Video-assisted Thoracoscopic Surgery Completed NCT02439905 Phase 4 Dexmedetomidine;Placebo control
14 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
15 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
16 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
17 trūFreeze® Palliative Esophageal Cancer Recruiting NCT03243734 Phase 4
18 Intrathoracic Esophagogastric Anastomosis After Robot Assisted Minimally Invasive Esophagectomy Using STRATAFIX Recruiting NCT02609425 Phase 4
19 Radiofrequency in the Treatment of Barrett's Oesophagus Recruiting NCT02558504 Phase 4
20 Iron Replacement in Oesophagogastric Neoplasia Recruiting NCT01927328 Phase 4 Iron isomaltoside 1000
21 Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
22 Lobaplation or Cisplatin in Adjuvant Chemotherapy for Esophageal Carcinoma Not yet recruiting NCT03413436 Phase 4 Lobaplatin;Cisplatin
23 The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I Not yet recruiting NCT02845479 Phase 4
24 Barretts oEsophageal Resection With Steroid Therapy Trial Not yet recruiting NCT02004782 Phase 4 Prednisolone;Placebo Oral Tablet
25 Traditional Three Incisions vs Minimally Invasive Thoracol-laparoscopic Esophagectomy for Esophageal Cancer Unknown status NCT02355249 Phase 3
26 Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer Unknown status NCT00509561 Phase 2, Phase 3 capecitabine;cisplatin
27 a Multicentric Randomized Controlled Trial of Self-Expandable Esophageal Radiation Stent Unknown status NCT01054274 Phase 3
28 Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial Unknown status NCT02319187 Phase 3 S1;S-1;irinotecan
29 Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002884 Phase 3 chemotherapy;cisplatin;fluorouracil
30 Comparable Study of Different Radiation Dose in Esophageal Carcinoma Unknown status NCT01937208 Phase 3 concurrent chemotherapy with radiation
31 Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer Unknown status NCT00686114 Phase 3 Paclitaxel;Cisplatin;Tarceva
32 Study of Lobaplatin,5-Fluorouracil and Leucovorin for the Treatment of Esophageal Carcinoma Unknown status NCT01034683 Phase 3 lobaplatin , 5-FU ,leucovorin
33 Combination Chemotherapy in Treating Patients With Esophageal Cancer Unknown status NCT00041262 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil
34 Esophagectomy: Sweet Versus Ivor-Lewis Unknown status NCT01047111 Phase 3
35 Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer Unknown status NCT00052910 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil;leucovorin calcium
36 Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0 Unknown status NCT01398449 Phase 3
37 Esophagectomy Associated Respiratory Complications: Ivor-Lewis Versus Sweet Approaches Unknown status NCT01053182 Phase 3
38 Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002883 Phase 3 cisplatin;fluorouracil
39 A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia Unknown status NCT00357682 Phase 3 Esomeprazole;Esomeprazole;Aspirin
40 Impact of the Techniques for Intrathoracic Esophagogastric Anastomosis on Outcome in Ivor-Lewis Oesophagectomy Unknown status NCT01242124 Phase 2, Phase 3
41 Three Field Radical Esophagectomy Versus Two Field Esophagectomy - a Prospective Trial Unknown status NCT00193817 Phase 3
42 The Effects of Gastric Tube on the Quality of Life and Nutritional Status After Ivor-Lewis Esophagectomy Unknown status NCT01361750 Phase 3
43 Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy Unknown status NCT01402180 Phase 2, Phase 3 chemotherapy;chemotherapy
44 Comparison Study of Brachytherapy and Endoscopic Stenting for Dysphagia in Esophago-Gastric Junction Cancer Unknown status NCT01786278 Phase 2, Phase 3
45 Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols Unknown status NCT01496521 Phase 3 Aspirin
46 Early Oral Feeding Following Thoracolaparoscopic Oesophagectomy in Patients With Esophageal Cancer Completed NCT01998230 Phase 3
47 Radiation Therapy and Combination Chemotherapy With or Without Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery Completed NCT00416858 Phase 3 cisplatin;fluorouracil
48 Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer Completed NCT00047112 Phase 3 cisplatin;fluorouracil
49 A Study of Chemoradiation Associated With Nimotuzumab as the Treatment of Locally Advanced Esophageal Cancer Completed NCT01249352 Phase 2, Phase 3 Nimotuzumab;Cisplatin;Fluorouracil
50 Surgery or Chemoradiation for Esophageal Cancer Completed NCT01032967 Phase 3

Search NIH Clinical Center for Esophageal Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Esophageal Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Esophageal Cancer:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Esophageal Cancer:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 23904171 21498393 22996367 19304471 22555974 15800326 23650429 21325070 24218514 8170938 12242449

Cochrane evidence based reviews: esophageal neoplasms

Genetic Tests for Esophageal Cancer

Genetic tests related to Esophageal Cancer:

# Genetic test Affiliating Genes
1 Carcinoma of Esophagus 29
2 Esophageal Neoplasm 29

Anatomical Context for Esophageal Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Esophageal Cancer:

19
The Esophagus

MalaCards organs/tissues related to Esophageal Cancer:

41
Lung, Lymph Node, Testes, T Cells, Liver, Breast, Bone

Publications for Esophageal Cancer

Articles related to Esophageal Cancer:

(show top 50) (show all 2297)
# Title Authors Year
1
Outcomes of esophagectomy after chemotherapy with biweekly docetaxel plus cisplatin and fluorouracil for advanced esophageal cancer: a retrospective cohort analysis. ( 29966526 )
2018
2
The Prediction of Deterioration of Nutritional Status during Chemoradiation Therapy in Patients with Esophageal Cancer. ( 29324061 )
2018
3
Recent progress in perioperative management of patients undergoing esophagectomy for esophageal cancer. ( 29951987 )
2018
4
Pulmonary actinomycosis mimicking a lung metastasis from esophageal cancer; a case report. ( 29486747 )
2018
5
Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer. ( 29948480 )
2018
6
Esophageal cancer male to female incidence ratios in Africa: A systematic review and meta-analysis of geographic, time and age trends. ( 29414631 )
2018
7
Anaphylatoxin C3a: A potential biomarker for esophageal cancer diagnosis. ( 29435296 )
2018
8
The Association Between Statin Use After Diagnosis and Mortality Risk in Patients With Esophageal Cancer: A Retrospective Cohort Study of United States Veterans. ( 29946180 )
2018
9
The Role of PET-Based Radiomic Features in Predicting Local Control of Esophageal Cancer Treated with Concurrent Chemoradiotherapy. ( 29967326 )
2018
10
Correction to: Comprehensive Registry of Esophageal Cancer in Japan, 2011. ( 29948478 )
2018
11
The role of endosonography prior to endoscopic treatment of esophageal cancer. ( 29963792 )
2018
12
Early diagnostic potential of<i>APC</i>hypermethylation in esophageal cancer. ( 29440928 )
2018
13
Diagnosing conduit leak after esophagectomy for esophageal cancer by computed tomography leak protocol and standard esophagram: Is old school still the best? ( 29414520 )
2018
14
Intake of Dietary One-Carbon Metabolism-Related B Vitamins and the Risk of Esophageal Cancer: A Dose-Response Meta-Analysis. ( 29954131 )
2018
15
Comprehensive Registry of Esophageal Cancer in Japan, 2011. ( 29948477 )
2018
16
Near infrared fluorescent peptide nanoparticles for enhancing esophageal cancer therapeutic efficacy. ( 29973582 )
2018
17
The relationship between esophageal cancer, chagasic megaesophagus and HPV: myths, tales or reality? ( 29687834 )
2018
18
[The Efficacy of Definitive Chemoradiotherapy for Thoracic Esophageal Cancer on the Point of View Salvage Surgery]. ( 29362320 )
2018
19
<sup>18</sup> F-Fluorodeoxyglucose positron emission tomography can be used to determine the indication for endoscopic resection of superficial esophageal cancer. ( 29953743 )
2018
20
Future Perspectives of Surgery for Esophageal Cancer. ( 29962387 )
2018
21
Cervicothoracoscopic Approach for Esophageal Cancer in a Patient with Right-Sided Aortic Arch. ( 29411200 )
2018
22
Hot Tea and Esophageal Cancer. ( 29404600 )
2018
23
Outcome of Patients Treated Within and Outside a Randomized Clinical Trial on Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: Extrapolation of a Randomized Clinical Trial (CROSS). ( 29948420 )
2018
24
The ability of silver(I) thiocyanate 4-methoxyphenyl phosphine to induce apoptotic cell death in esophageal cancer cells is correlated to mitochondrial perturbations. ( 29430579 )
2018
25
Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study. ( 29433514 )
2018
26
SLC52A3 expression is activated by NF-I_B p65/Rel-B and serves as a prognostic biomarker in esophageal cancer. ( 29428966 )
2018
27
An explanatory and predictive model of the variation in esophageal cancer incidence on the basis of changes in the exposure to risk factors. ( 29324583 )
2018
28
Role of<i>MLH1</i>methylation in esophageal cancer carcinogenesis and its clinical significance. ( 29440913 )
2018
29
Role of ALDH1 in the prognosis of esophageal cancer and its relationship with tumor microenvironment. ( 28888039 )
2018
30
Impact of change in serum albumin level during and after chemoradiotherapy in patients with locally advanced esophageal cancer. ( 29951984 )
2018
31
Thoracoscopic resection of esophageal cancer with a tracheal diverticulum. ( 29067556 )
2018
32
Salvage Surgery for Esophageal Cancer: How to Improve Outcomes? ( 29417405 )
2018
33
Postoperative Pneumonia is Associated with Long-Term Oncologic Outcomes of Definitive Chemoradiotherapy Followed by Salvage Esophagectomy for Esophageal Cancer. ( 29980971 )
2018
34
Neoadjuvant Treatments for Locally Advanced, Resectable Esophageal Cancer: A Network Meta-Analysis. ( 29441562 )
2018
35
Minimally invasive esophagectomy may contribute to long-term respiratory function after esophagectomy for esophageal cancer. ( 29444214 )
2018
36
Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer. ( 29963201 )
2018
37
Efficacy of endoscopic screening for esophageal cancer in China (ESECC): design and preliminary results of a population-based randomised controlled trial. ( 29306867 )
2018
38
Immediate extubation after esophagectomy with three-field lymphadenectomy enables early ambulation in patients with thoracic esophageal cancer. ( 29951981 )
2018
39
Nutritional optimization during neoadjuvant therapy prior to surgical resection of esophageal cancer-a narrative review. ( 29024949 )
2018
40
The effect of curcumin on cell adhesion of human esophageal cancer cell. ( 29424917 )
2018
41
Efficacy comparison of transcervical video-assisted mediastinoscopic lymphadenectomy combined with left transthoracic esophagectomy versus right transthoracic esophagectomy for esophageal cancer treatment. ( 29426329 )
2018
42
Downregulation of HuR Inhibits the Progression of Esophageal Cancer through Interleukin-18. ( 28231690 )
2018
43
Outcomes of abdominal esophageal cancer patients who were treated with esophagectomy. ( 29435289 )
2018
44
Validation of the eighth clinical American Joint Committee on Cancer stage grouping for esophageal cancer. ( 29235888 )
2018
45
A new clinical staging system for esophageal cancer to predict survival after definitive chemoradiation or radiotherapy. ( 29961898 )
2018
46
Transgastric Endoscopic Submucosal Dissection of Esophageal Cancer with Cervical Stricture. ( 29420854 )
2018
47
Comparative effectiveness of upfront esophagectomy versus induction chemoradiation in clinical stage T2N0 esophageal cancer: A decision analysis. ( 29428700 )
2018
48
[Retracted] Effects of cyclin E gene silencing on the proliferation of esophageal cancer cell lines, EC9706, Eca109 and KYSE30. ( 29328443 )
2018
49
Detection of HPV16 in Esophageal Cancer in a High-Incidence Region of Malawi. ( 29439548 )
2018
50
Stenting in Palliation of Unresectable Esophageal Cancer. ( 29946788 )
2018

Variations for Esophageal Cancer

UniProtKB/Swiss-Prot genetic disease variations for Esophageal Cancer:

75
# Symbol AA change Variation ID SNP ID
1 TGFBR2 p.Glu526Gln VAR_015816 rs121918714

ClinVar genetic disease variations for Esophageal Cancer:

6
(show top 50) (show all 474)
# Gene Variation Type Significance SNP ID Assembly Location
1 LZTS1 NM_021020.3(LZTS1): c.85T> C (p.Ser29Pro) single nucleotide variant Pathogenic rs28937897 GRCh37 Chromosome 8, 20112608: 20112608
2 LZTS1 NM_021020.3(LZTS1): c.85T> C (p.Ser29Pro) single nucleotide variant Pathogenic rs28937897 GRCh38 Chromosome 8, 20255097: 20255097
3 LZTS1 NM_021020.3(LZTS1): c.355A> G (p.Lys119Glu) single nucleotide variant Pathogenic rs119473032 GRCh37 Chromosome 8, 20111087: 20111087
4 LZTS1 NM_021020.3(LZTS1): c.355A> G (p.Lys119Glu) single nucleotide variant Pathogenic rs119473032 GRCh38 Chromosome 8, 20253576: 20253576
5 WWOX NM_016373.3(WWOX): c.872T> C (p.Leu291Pro) single nucleotide variant Pathogenic rs119487098 GRCh37 Chromosome 16, 78466465: 78466465
6 WWOX NM_016373.3(WWOX): c.872T> C (p.Leu291Pro) single nucleotide variant Pathogenic rs119487098 GRCh38 Chromosome 16, 78432568: 78432568
7 RNF6 NM_005977.3(RNF6): c.305G> A (p.Arg102Lys) single nucleotide variant Pathogenic rs121434522 GRCh37 Chromosome 13, 26789714: 26789714
8 RNF6 NM_005977.3(RNF6): c.305G> A (p.Arg102Lys) single nucleotide variant Pathogenic rs121434522 GRCh38 Chromosome 13, 26215577: 26215577
9 RNF6 NM_005977.3(RNF6): c.724G> A (p.Ala242Thr) single nucleotide variant Pathogenic rs121434523 GRCh37 Chromosome 13, 26789295: 26789295
10 RNF6 NM_005977.3(RNF6): c.724G> A (p.Ala242Thr) single nucleotide variant Pathogenic rs121434523 GRCh38 Chromosome 13, 26215158: 26215158
11 RNF6 NM_005977.3(RNF6): c.731G> A (p.Gly244Asp) single nucleotide variant Pathogenic rs121434524 GRCh37 Chromosome 13, 26789288: 26789288
12 RNF6 NM_005977.3(RNF6): c.731G> A (p.Gly244Asp) single nucleotide variant Pathogenic rs121434524 GRCh38 Chromosome 13, 26215151: 26215151
13 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
14 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh38 Chromosome 18, 51065548: 51065548
15 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh37 Chromosome 18, 48593406: 48593406
16 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh38 Chromosome 18, 51067036: 51067036
17 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
18 TP53 NM_000546.5(TP53): c.524G> A (p.Arg175His) single nucleotide variant Pathogenic rs28934578 GRCh37 Chromosome 17, 7578406: 7578406
19 TP53 NM_000546.5(TP53): c.524G> A (p.Arg175His) single nucleotide variant Pathogenic rs28934578 GRCh38 Chromosome 17, 7675088: 7675088
20 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
21 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
22 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
23 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
24 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh38 Chromosome 17, 7674238: 7674238
25 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
26 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
27 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
28 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
29 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
30 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
31 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
32 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
33 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
34 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
35 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
36 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
37 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
38 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
39 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
40 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
41 TGFBR2 NM_003242.5(TGFBR2): c.1576G> C (p.Glu526Gln) single nucleotide variant Pathogenic rs121918714 GRCh37 Chromosome 3, 30732963: 30732963
42 TGFBR2 NM_003242.5(TGFBR2): c.1576G> C (p.Glu526Gln) single nucleotide variant Pathogenic rs121918714 GRCh38 Chromosome 3, 30691471: 30691471
43 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
44 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
45 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
46 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
47 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
48 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
49 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
50 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297

Cosmic variations for Esophageal Cancer:

9
(show top 50) (show all 10802)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM5049514 ZSCAN18 oesophagus,NS,carcinoma,squamous cell carcinoma c.838+2T>A p.? 19:58086172-58086172 23
2 COSM2765083 ZNF831 oesophagus,NS,carcinoma,squamous cell carcinoma c.605T>C p.L202P 20:59191624-59191624 23
3 COSM5048967 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.768C>G p.Y256* 17:82831687-82831687 23
4 COSM4834899 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.170C>G p.S57* 17:82832285-82832285 23
5 COSM5046823 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.37C>A p.H13N 17:82832418-82832418 23
6 COSM5047811 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.938C>G p.S313C 17:82831517-82831517 23
7 COSM5047812 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.668C>G p.S223* 17:82831787-82831787 23
8 COSM5046772 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.80G>C p.C27S 17:82832375-82832375 23
9 COSM5047907 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.777C>A p.Y259* 17:82831678-82831678 23
10 COSM2158206 ZNF365 oesophagus,NS,carcinoma,squamous cell carcinoma c.712G>A p.E238K 10:62376905-62376905 23
11 COSM5047556 ZNF230 oesophagus,NS,carcinoma,squamous cell carcinoma c.87G>C p.Q29H 19:44008861-44008861 23
12 COSM5047304 ZNF207 oesophagus,NS,carcinoma,squamous cell carcinoma c.1162C>T p.R388W 17:32369340-32369340 23
13 COSM5049372 ZNF185 oesophagus,NS,carcinoma,squamous cell carcinoma c.71A>T p.E24V 23:152919042-152919042 23
14 COSM389658 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.6845G>A p.R2282Q 8:76853766-76853766 23
15 COSM5048796 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.2120C>G p.S707C 8:76706208-76706208 23
16 COSM4546868 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.4099G>A p.D1367N 8:76851020-76851020 23
17 COSM751681 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.9517C>T p.P3173S 8:76863231-76863231 23
18 COSM5048642 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.439G>T p.E147* 8:76704527-76704527 23
19 COSM5048093 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.9060G>T p.L3020F 8:76855981-76855981 23
20 COSM5047474 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.10574C>T p.S3525F 8:76864288-76864288 23
21 COSM5048233 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.6266C>A p.P2089H 8:76853187-76853187 23
22 COSM2876375 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.8374G>A p.G2792R 8:76855295-76855295 23
23 COSM5049149 ZFHX3 oesophagus,NS,carcinoma,squamous cell carcinoma c.4628G>T p.R1543L 16:72798054-72798054 23
24 COSM3276999 ZFHX3 oesophagus,NS,carcinoma,squamous cell carcinoma c.359G>A p.G120E 16:72959787-72959787 23
25 COSM5049692 ZFHX3 oesophagus,NS,carcinoma,squamous cell carcinoma c.3497C>T p.P1166L 16:72829811-72829811 23
26 COSM5048958 ZFHX3 oesophagus,NS,carcinoma,squamous cell carcinoma c.4132C>T p.Q1378* 16:72798550-72798550 23
27 COSM5049693 ZFHX3 oesophagus,NS,carcinoma,squamous cell carcinoma c.3496C>T p.P1166S 16:72829812-72829812 23
28 COSM127037 ZFAT oesophagus,NS,carcinoma,squamous cell carcinoma c.143C>G p.S48* 8:134657578-134657578 23
29 COSM5048211 ZFAT oesophagus,NS,carcinoma,squamous cell carcinoma c.2249G>A p.R750H 8:134600626-134600626 23
30 COSM5047133 ZC3H7B oesophagus,NS,carcinoma,squamous cell carcinoma c.476T>A p.L159Q 22:41330054-41330054 23
31 COSM5047865 ZC3H6 oesophagus,NS,carcinoma,squamous cell carcinoma c.637T>G p.F213V 2:112311827-112311827 23
32 COSM2250480 ZC3H14 oesophagus,NS,carcinoma,squamous cell carcinoma c.1793T>A p.L598* 14:88607288-88607288 23
33 COSM3481930 ZC3H11A oesophagus,NS,carcinoma,squamous cell carcinoma c.800C>T p.S267F 1:203831760-203831760 23
34 COSM5049679 YME1L1 oesophagus,NS,carcinoma,squamous cell carcinoma c.863-2A>G p.? 10:27134124-27134124 23
35 COSM2134440 YME1L1 oesophagus,NS,carcinoma,squamous cell carcinoma c.43C>T p.P15S 10:27149031-27149031 23
36 COSM5046790 XPO5 oesophagus,NS,carcinoma,squamous cell carcinoma c.2092T>C p.Y698H 6:43547676-43547676 23
37 COSM5047544 XIRP2 oesophagus,NS,carcinoma,squamous cell carcinoma c.5215G>A p.E1739K 2:167246607-167246607 23
38 COSM5047950 XIRP2 oesophagus,NS,carcinoma,squamous cell carcinoma c.4627G>C p.E1543Q 2:167246019-167246019 23
39 COSM5047255 WWC3 oesophagus,NS,carcinoma,squamous cell carcinoma c.2836C>T p.R946* 23:10136705-10136705 23
40 COSM5047360 WRN oesophagus,NS,carcinoma,squamous cell carcinoma c.1475C>T p.S492F 8:31087819-31087819 23
41 COSM5048456 WEE1 oesophagus,NS,carcinoma,squamous cell carcinoma c.1212G>T p.K404N 11:9581602-9581602 23
42 COSM5049604 WDR66 oesophagus,NS,carcinoma,squamous cell carcinoma c.1475A>T p.K492M 12:121954274-121954274 23
43 COSM5047589 WDR64 oesophagus,NS,carcinoma,squamous cell carcinoma c.94G>C p.E32Q 1:241687585-241687585 23
44 COSM5049378 VSIG8 oesophagus,NS,carcinoma,squamous cell carcinoma c.331A>G p.I111V 1:159858189-159858189 23
45 COSM5048553 VPS35L oesophagus,NS,carcinoma,squamous cell carcinoma c.1435G>A p.E479K 16:19628688-19628688 23
46 COSM5048755 VPS35L oesophagus,NS,carcinoma,squamous cell carcinoma c.2258C>T p.P753L 16:19669196-19669196 23
47 COSM5049353 VPS35L oesophagus,NS,carcinoma,squamous cell carcinoma c.2432A>G p.E811G 16:19682295-19682295 23
48 COSM5049350 VPS35L oesophagus,NS,carcinoma,squamous cell carcinoma c.2431G>T p.E811* 16:19682294-19682294 23
49 COSM5048194 VPS13D oesophagus,NS,carcinoma,squamous cell carcinoma c.11390G>A p.R3797Q 1:12385279-12385279 23
50 COSM3369233 VPS13D oesophagus,NS,carcinoma,squamous cell carcinoma c.8197+1G>A p.? 1:12327855-12327855 23

Copy number variations for Esophageal Cancer from CNVD:

7 (show top 50) (show all 64)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 32702 1 39027237 40780163 Amplification MYCL1 Esophageal cancer
2 35731 1 66691991 71187083 Deletion CTH Esophageal cancer
3 38511 10 10309026 19155158 Deletion Esophageal cancer
4 41416 10 17811791 65388337 Amplification Esophageal cancer
5 43899 10 50393324 70694787 Deletion Esophageal cancer
6 48565 11 100815801 103042620 Amplification BIRC2 Esophageal cancer
7 48566 11 100815801 103042620 Amplification BIRC3 Esophageal cancer
8 48567 11 100815801 103042620 Amplification YAP1 Esophageal cancer
9 55251 11 50256798 61426521 Deletion Esophageal cancer
10 58612 11 68753086 69985447 Amplification CCND1 Esophageal cancer
11 58613 11 68753086 69985447 Amplification CTTN Esophageal cancer
12 58614 11 68753086 69985447 Amplification FGF19 Esophageal cancer
13 58615 11 68753086 69985447 Amplification FGF3 Esophageal cancer
14 58616 11 68753086 69985447 Amplification FGF4 Esophageal cancer
15 58617 11 68753086 69985447 Amplification MYEOV Esophageal cancer
16 58701 11 69200000 70700000 Gain PPFIA1 Esophageal cancer
17 61418 12 1 132078379 Deletion Esophageal cancer
18 79288 13 68772537 113042980 Deletion Esophageal cancer
19 80978 14 1 105311216 Deletion Esophageal cancer
20 83027 14 19100000 23600000 Gain NFATC4 Esophageal cancer
21 84103 14 23600000 31800000 Gain ARHGAP5 Esophageal cancer
22 84107 14 23600000 36900000 Gain PAX9 Esophageal cancer
23 85295 14 42828345 44176016 Deletion Esophageal cancer
24 111151 17 35097918 35138441 Copy number ERBB2 Esophageal cancer
25 119155 18 1 1118244 Amplification TYMS Esophageal cancer
26 119156 18 1 1118244 Amplification YES1 Esophageal cancer
27 121678 18 46081464 51919972 Deletion SMAD4 Esophageal cancer
28 137284 2 141590067 141951947 Deletion LRP1B Esophageal cancer
29 151504 20 22140447 26145930 Amplification PYGB Esophageal cancer
30 157032 21 1 29932926 Deletion Esophageal cancer
31 160899 22 16558724 17937900 Amplification BID Esophageal cancer
32 160900 22 16558724 17937900 Amplification CLDN5 Esophageal cancer
33 161388 22 18577713 20667607 Amplification CRKL Esophageal cancer
34 161389 22 18577713 20667607 Amplification MAPK1 Esophageal cancer
35 163870 22 31889314 32003182 Amplification LARGE Esophageal cancer
36 166067 3 1 199344050 Deletion Esophageal cancer
37 169829 3 14700000 43600000 Loss RAB5A Esophageal cancer
38 171482 3 168801287 168851758 Amplification EVI1 Esophageal cancer
39 171491 3 168867391 169381563 Amplification MDS1 Esophageal cancer
40 173071 3 189400000 193800000 Gain TP63 Esophageal cancer
41 174749 3 32100000 54400000 Loss SCN10A Esophageal cancer
42 175197 3 3800000 87200000 Loss ATXN7 Esophageal cancer
43 175734 3 43600000 51400000 Loss CTDSPL Esophageal cancer
44 177631 3 59735036 61237133 Deletion FHIT Esophageal cancer
45 179189 3 8700000 14700000 Loss RAF1 Esophageal cancer
46 179592 3 95917505 101945216 Amplification MINA Esophageal cancer
47 190878 4 91972774 162358674 Deletion CASP6 Esophageal cancer
48 190879 4 91972774 162358674 Deletion SMAD1 Esophageal cancer
49 191757 5 10051329 11800765 Amplification CTNND2 Esophageal cancer
50 198525 5 25700000 76400000 Loss F2R Esophageal cancer

Expression for Esophageal Cancer

Search GEO for disease gene expression data for Esophageal Cancer.

Pathways for Esophageal Cancer

Pathways related to Esophageal Cancer according to KEGG:

37
# Name Kegg Source Accession
1 MicroRNAs in cancer hsa05206

Pathways related to Esophageal Cancer according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.64 EGFR HRAS PIK3CA SMAD4 TGFBR2 TP53
2
Show member pathways
12.61 DCC EGFR HRAS PIK3CA SMAD4 TGFBR2
3 12.52 DCC EGFR HRAS PIK3CA SMAD4 TGFBR2
4
Show member pathways
12.43 EGFR HRAS PIK3CA TP53
5
Show member pathways
12.41 EGFR HRAS PIK3CA TP53
6
Show member pathways
12.36 EGFR HRAS PIK3CA TGFBR2 TP53
7
Show member pathways
12.33 EGFR HRAS PIK3CA SMAD4 TGFBR2 TP53
8 12.31 HRAS PIK3CA SMAD4 TGFBR2 TP53
9 12.16 EGFR HRAS MIR21 PIK3CA TP53
10
Show member pathways
12.11 HRAS PIK3CA TGFBR2 TP53
11 12.1 HRAS PIK3CA TGFBR2 TP53
12 12.08 EGFR HRAS PIK3CA TP53
13 12.07 EGFR SMAD4 TGFBR2 TP53
14
Show member pathways
12.04 EGFR HRAS PIK3CA TGFBR2
15
Show member pathways
12.02 EGFR HRAS PIK3CA SMAD4 TGFBR2
16 12.02 DCC EGFR SMAD4 TGFBR2 TP53
17 11.99 EGFR HRAS PIK3CA TP53
18 11.91 HRAS PIK3CA SMAD4 TP53
19
Show member pathways
11.86 EGFR HRAS PIK3CA WWOX
20 11.8 EGFR HRAS MIR126 MIR16-2 MIR21 MIR30E
21
Show member pathways
11.79 EGFR HRAS PIK3CA
22 11.78 EGFR RNF6 SMAD4
23 11.77 HRAS PIK3CA SMAD4 TGFBR2
24 11.74 MIR106A MIR16-2 MIR30E
25
Show member pathways
11.69 EGFR HRAS PIK3CA SMAD4 TGFBR2
26 11.68 EGFR HRAS TP53
27 11.67 EGFR SMAD4 TGFBR2
28 11.66 HRAS SMAD4 TGFBR2
29 11.61 HRAS PIK3CA TP53
30 11.55 HRAS SMAD4 TGFBR2
31 11.55 EGFR HRAS PIK3CA TP53
32 11.25 EGFR HRAS TP53
33 11.23 EGFR HRAS PIK3CA
34 10.8 EGFR HRAS
35 10.73 EGFR HRAS SMAD4 TGFBR2

GO Terms for Esophageal Cancer

Biological processes related to Esophageal Cancer according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.76 EGFR HRAS MIR126 MIR21
2 axon guidance GO:0007411 9.73 DCC HRAS PIK3CA SMAD4
3 transforming growth factor beta receptor signaling pathway GO:0007179 9.7 MIR21 SMAD4 TGFBR2
4 positive regulation of protein kinase B signaling GO:0051897 9.67 EGFR MIR126 MIR21 PIK3CA
5 epidermal growth factor receptor signaling pathway GO:0007173 9.58 EGFR HRAS PIK3CA
6 negative regulation of cardiac muscle hypertrophy GO:0010614 9.54 MIR21 SMAD4
7 negative regulation of macroautophagy GO:0016242 9.51 LZTS1 PIK3CA
8 positive regulation of epithelial to mesenchymal transition GO:0010718 9.5 MIR21 SMAD4 TGFBR2
9 secondary palate development GO:0062009 9.49 SMAD4 TGFBR2
10 positive regulation of connective tissue replacement GO:1905205 9.48 MIR16-2 MIR34A
11 ERBB2 signaling pathway GO:0038128 9.43 EGFR HRAS PIK3CA
12 negative regulation of cell proliferation GO:0008285 9.43 HRAS MIR16-2 MIR21 SMAD4 TGFBR2 TP53
13 negative regulation of vascular endothelial cell proliferation GO:1905563 9.33 MIR126 MIR30E MIR34A
14 gene silencing by miRNA GO:0035195 9.17 MIR106A MIR126 MIR148A MIR16-2 MIR21 MIR30E

Molecular functions related to Esophageal Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.17 MIR106A MIR126 MIR148A MIR16-2 MIR21 MIR30E

Sources for Esophageal Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....